4e bp1

Antibodies were obtained from Cell Signaling, Boston, MA, USA (Smad2 #5339, pERK1/2^T202/Y204, ERK1/2, pFoxO3a^T32, p-mTOR^S2448, mTOR, rictor, raptor, GβL, p4E-BP1^S65, 4E-BP1, pAkt^S473, Akt, ATG7, LC3b, SGK, pULK1^S757), Novus Biologicals, Littleton, CO, USA (eIf3f Lamp2), Epitomics, Burlingame, CA, USA (pSmad3^S423/S425, Smad3), Invitrogen, Grand Island, NY, USA (pSmad2^S465/S467), Abcam, Cambridge, MA, USA (p70S6k, p-p70S6k^T389, Myogenin, FoxO3a, p62, ULK1), Millipore, Billerica, MA, USA (pFoxO3a^S252, p21), ECM Biosciences, Versailles, KY, USA (atrogin-1), and Santa Cruz Biotechnology, Dallas, TX, USA (GAPDH). Secondary antibodies were obtained from GE Healthcare, Pittsburgh, PA, USA (anti-rabbit, anti-mouse, anti-rat) and Sigma-Aldrich, St Louis, MO, USA (anti-goat).

Tissues were snap-frozen in liquid nitrogen and stored at −80 °C. Pulverized frozen tumor samples were lysed in radioimmunoprecipitation assay (RIPA) buffer and the total proteins were extracted, separated, and transferred using standard procedures. Antibodies were purchased from BD Transduction Laboratories: SMARCB1 (1/500, 612110); Cell Signaling Technology: Akt (1/2000, #9272), P-Akt (Ser473) (1/2000, #4060), CDK4 (1/2000, #2906), CDK6 (1/2000, #3136), Cyclin D1 (1/3000, #2926), merlin (1/1000, #6995), p27 (1/1000, #2552), P-Rb (1/1000, #8516), S6 (1/1000, #2317), P-S6 (Ser 235/236) (1/4000, #4858), 4E-BP1 (1/2000, #9452); Novus Biologicals: GAPDH (1/5000, NB300-221), PTCH1 (1/1000, MAB41051), RB1 (1/50, NB120-3077), SHH (1/500, AF464); R&D Systems: GLI-1 (1/1000, AF3455); Santa Cruz Biotechnology: p16 (1/3000, sc-1207) and Thermo Scientific: p21^WAF1 (1/1000, MS-387-P0). All uncropped scans of western blots are provided in Supplementary Fig. 7.